Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011842 | 1.00 | TP53 (0.40) | TP53LMNAPOLBMAPTTHRB | |
| SCHEMBL6011838 | 1.00 | TP53 (0.40) | TP53LMNAPOLBMAPTTHRB | |
| SCHEMBL6011932 | 0.90 | TP53 (0.42) | TP53LMNAPOLBTHRBMC4R | |
| SCHEMBL6011595 | 0.90 | TP53 (0.42) | TP53LMNAPOLBTHRBMC4R | |
| SCHEMBL6794152 | 0.90 | TP53 (0.42) | TP53LMNAPOLBTHRBMC4R | |
| SCHEMBL6011592 | 0.90 | TP53 (0.42) | TP53LMNAPOLBTHRBMC4R | |
| SCHEMBL674830 | 0.86 | CYP2D6 (0.38) | — | |
| SCHEMBL7156739 | 0.85 | HRH3 (0.35) | TP53LMNATHRBMC4R | |
| SCHEMBL5077602 | 0.83 | KDM4E (0.40) | LMNAMAPT | |
| SCHEMBL5077604 | 0.83 | KDM4E (0.40) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | TP53 3771/4885LMNA 3266/4885POLB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.